 |
|
New clinical trial for patients with asbestos-associated lung cancer
June 26, 2008Investigational therapy may help avoid lung removal surgery for patients with pleural mesothelioma
The Mesothelioma Center within the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian Hospital and Columbia University Medical Center is now recruiting patients for a clinical research study of a new targeted radiation and chemotherapy protocol for pleural mesothelioma, a cancer of the lung's lining that is almost always caused by previous exposure to asbestos.
The standard treatment for pleural mesothelioma is currently surgery to remove the patient's lung - a potentially debilitating consequence.
"Current surgical and chemotherapy treatments of patients with malignant pleural mesothelioma are unsatisfactory, and have not been shown to significantly prolong survival. In this study, we will investigate whether a combination of chemotherapy and radiation targeted directly at the lung's lining can improve outcomes while avoiding surgery," says Dr. Robert Taub, the study's principal investigator, director of the Mesothelioma Center at NewYork-Presbyterian/Columbia and professor of clinical medicine at Columbia University College of Physicians and Surgeons. "In addition, this approach has shown to have minimal toxic side effects compared to systemic chemotherapy."
"This trial is also significant because our center is the only one nationwide that is offering this experimental therapy to treat pleural mesothelioma," added Dr. Taub. "We are very focused on offering these patients the best treatment that medical technology can offer while simultaneously working to preserve quality of life."
Researchers also anticipate that the radiation therapy will kill the cancer cells on surface of the lung while sparing other parts of the lung and surrounding vital tissues.
"Delivery of radiation therapy directly into the pleural cavity is a strategy that has been employed since 1945. Today, direct injection of radioactive isotope P-32 may prove to be a significant and effective therapeutic approach for selected mesothelioma patients," adds Dr. Rashid Fawwaz, study co-investigator, radiologist at NewYork-Presbyterian/Columbia and professor of clinical radiology at Columbia University College of Physicians and Surgeons.
"Overall, it is hoped that this study will decrease the need for patients to undergo radical surgery," states Dr. Joshua Sonett, study co-investigator, chief of general thoracic surgery, surgical director of the Lung Transplant Program and surgical director of the High-Risk Lung Assessment Program at NewYork-Presbyterian/Columbia and professor of clinical surgery at Columbia University College of Physicians and Surgeons.
Participating patients will receive several rounds of targeted chemotherapy using the drugs cisplatin and doxorubicin via surgically implanted catheters. Some patients will be randomly selected to receive additional systemic (intravenous) chemotherapy using the drugs cisplatin and pemetrexed. All patients will receive targeted radiotherapy using the P-32 radioisotope. Patients may elect to receive additional surgical treatment, including removal of the affected lung lining or lung. Subsequently, patients will be offered outpatient systemic chemotherapy with cisplatin and pemetrexed.
The investigators previously led a prospective study that employed a similar protocol for patients with pleural mesothelioma as well as those with the more retractable sarcomatous disease. Completed in 2002, the study reported a median survival of 70 months, and a three-year survival of 67 percent (American Journal of Clinical Oncology, February 2008).
New York- Presbyterian Hospital/Columbia University Medical Center
"Current surgical and chemotherapy treatments of patients with malignant pleural mesothelioma are unsatisfactory, and have not been shown to significantly prolong survival. In this study, we will investigate whether a combination of chemotherapy and radiation targeted directly at the lung's lining can improve outcomes while avoiding surgery," says Dr. Robert Taub, the study's principal investigator, director of the Mesothelioma Center at NewYork-Presbyterian/Columbia and professor of clinical medicine at Columbia University College of Physicians and Surgeons. "In addition, this approach has shown to have minimal toxic side effects compared to systemic chemotherapy."
"This trial is also significant because our center is the only one nationwide that is offering this experimental therapy to treat pleural mesothelioma," added Dr. Taub. "We are very focused on offering these patients the best treatment that medical technology can offer while simultaneously working to preserve quality of life."
Researchers also anticipate that the radiation therapy will kill the cancer cells on surface of the lung while sparing other parts of the lung and surrounding vital tissues.
"Delivery of radiation therapy directly into the pleural cavity is a strategy that has been employed since 1945. Today, direct injection of radioactive isotope P-32 may prove to be a significant and effective therapeutic approach for selected mesothelioma patients," adds Dr. Rashid Fawwaz, study co-investigator, radiologist at NewYork-Presbyterian/Columbia and professor of clinical radiology at Columbia University College of Physicians and Surgeons.
"Overall, it is hoped that this study will decrease the need for patients to undergo radical surgery," states Dr. Joshua Sonett, study co-investigator, chief of general thoracic surgery, surgical director of the Lung Transplant Program and surgical director of the High-Risk Lung Assessment Program at NewYork-Presbyterian/Columbia and professor of clinical surgery at Columbia University College of Physicians and Surgeons.
Participating patients will receive several rounds of targeted chemotherapy using the drugs cisplatin and doxorubicin via surgically implanted catheters. Some patients will be randomly selected to receive additional systemic (intravenous) chemotherapy using the drugs cisplatin and pemetrexed. All patients will receive targeted radiotherapy using the P-32 radioisotope. Patients may elect to receive additional surgical treatment, including removal of the affected lung lining or lung. Subsequently, patients will be offered outpatient systemic chemotherapy with cisplatin and pemetrexed.
The investigators previously led a prospective study that employed a similar protocol for patients with pleural mesothelioma as well as those with the more retractable sarcomatous disease. Completed in 2002, the study reported a median survival of 70 months, and a three-year survival of 67 percent (American Journal of Clinical Oncology, February 2008).
New York- Presbyterian Hospital/Columbia University Medical Center
Mesothelioma Current Events and Mesothelioma News RSSNew research group offers hope to asbestosis sufferers
The Asbestos Research Group, offering hope to sufferers of asbestos-related diseases, was launched at The Wesley Research Institute today.
First biomarker discovered that predicts prostate cancer outcome
Mayo Clinic researchers have identified the first immune molecule that appears to play a role in prostate cancer development and in predicting cancer recurrence and progression after surgery.
Frog molecule could provide drug treatment for brain tumours
Known as Amphinase, the molecule recognises the sugary coating found on a tumour cell and binds to its surface before invading the cell and inactivating the RNA it contains, causing the tumour to die.
Talcum powder stunts growth of lung tumors
Talcum powder has been used for generations to soothe babies' diaper rash and freshen women's faces. But University of Florida researchers report the household product has an additional healing power: The ability to stunt cancer growth by cutting the flow of blood to metastatic lung tumors.
Asbestos disease projections too low
Current predictions of the future incidence of asbestos-related disease have been substantially underestimated, according to new modelling to be presented in Melbourne today by an epidemiologist from The Australian National University.
Chemo combination improves survival in asbestos-related cancer
People with mesothelioma — a form of cancer associated with asbestos exposure — have a higher survival rate when treated with a combination of two cancer drugs, a large multicenter study finds.
'Signature' of chromosome instability predicts cancer outcomes
Microscopic examination of tumor specimens cannot always predict a cancer's aggressiveness, leading to increased interest in molecular approaches to diagnosis.
Clinical trial confirms novel EGFR antibody targets tumors but not normal tissues
The Ludwig Institute for Cancer Research (LICR) and Life Science Pharmaceuticals (LSP) today announced the results of the first clinical trial of monoclonal antibody (mAb) 806, which demonstrate that 806 specifically targets epidermal growth factor receptor (EGFR) on a wide range of tumor types but has no uptake by normal tissues.
Elevated blood levels of a protein are linked to asbestos-induced cancers
Researchers at New York University School of Medicine and Wayne State University have found a molecule that reveals the early stages of pleural mesothelioma, a chest cancer caused by asbestos.
UK faces asbestos epidemic
The United Kingdom is facing an epidemic of mesothelioma (a malignant tumour of the lung lining) among workers exposed to asbestos, warn senior doctors in this week's BMJ. There are now over 1800 mesothelioma deaths per year in Britain (more than one in 200 of all deaths in men and almost one in 1000 in women) and the number is still increasing. As exposure in the UK continued until 1980 the peak of the epidemic is still to come, and we need a strategy to manage these patients, they write. Some patients and their doctors desperately seek radical surgery as their only hope, but others have doubts about the evidence. But irrespective of whether radical surgery will be considered, all doctors n
More Mesothelioma Current Events and Mesothelioma News Articles
 | Surviving Mesothelioma and Other Cancers: A Patient's Guide by Paul Kraus |
 | 100 Questions & Answers About Mesothelioma (100 Questions & Answers about . . .) by Harvey I. Pass, John A. Dingell, Susan Vento Whether you’re a newly diagnosed Mesothelioma patient, a survivor, or a friend or relative of either, this book offers help. The only book to provide the doctor’s and patient’s views, 100 Questions & Answers About Mesothelioma gives you authoritative, practical answers to your questions about treatment options, post-treatment quality of life, sources of support, legal options, and much... |
 | They Said Months. I Chose Years! A Mesothelioma Survivor's Story by J.R. O'Connor In October 2001, James O'Connor was diagnosed with mesothelioma, the asbestos caused cancer. His prognosis was less than a year to live. Surgery was not possible because of the position of the tumor and chemotherapy would decrease his quality of life and not significantly improve his length of life. His oncologist suggested that he take his wife on a cruise and start hospice care upon his return.... |
 | Mesothelioma (Martin Dunitz) Second author is with Mount Sinai Hospital, New York, NY. Presents a state-of-the-art review of this condition, from laboratory to the bedside, from diagnostic procedures through treatment, and from imaging and early detection to medico-legal issues. For clinicians and scientists and members of the legal... |
 | Malignant Mesothelioma: Advances in Pathogenesis, Diagnosis, and Translational Therapies Malignant mesothelioma is a rare form of cancer in which the cancer cells are found in the sac lining the chest (pleura) or abdomen (peritoneum). This lethal disease is associated with asbestos and has vast economic and legal implications. As the disease takes approximately twenty years to manifest itself in humans, a wave of diagnoses are expected in the near future. In the United States alone,... |
 | Mesothelioma, An Issue of Hematology/Oncology Clinics (The Clinics: Internal Medicine) by Hedy Lee Kindler Malignant mesothelioma is a disease in which malignant cells are found in the sac lining the pleura, the lining of the peritoneum or the lining of the pericardium. This issue discusses the pathology, diagnosis and treatment of this rare cancer which is associated with asbestos... |
 | How To Recognize and Treat Mesothelioma by Quick Easy Guides Though mesothelioma is a fairly rare cancer, several thousands of Americans are diagnosed with mesothelioma cancer each year - a rate that is expected to grow before it subsides. ...Written by experts in the field, Quick Easy Guides share little-known trade secrets and helpful hints to get you moving in the right direction.Quick Easy Guides gives you books you can judge by the cover. Our books... |
| SURVIVING MESOTHELIOMA & OTHER CANCERS (A Patient's Guide) by Paul Kraus | |
 | Mesothelioma: The Story of an Illness by Brenda McKessock |
 | Lung Cancer and Mesothelioma by Howard A. Gutman |
| © 2009 BrightSurf.com |